Cargando…

Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios

Biomarker testing is recommended for the accurate and timely diagnosis of Alzheimer's disease (AD). Using illustrative case narratives we consider how cerebrospinal fluid (CSF) biomarker tests may be used in different presentations of cognitive impairment to facilitate timely and differential d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouwman, Femke H., Frisoni, Giovanni B., Johnson, Sterling C., Chen, Xiaochun, Engelborghs, Sebastiaan, Ikeuchi, Takeshi, Paquet, Claire, Ritchie, Craig, Bozeat, Sasha, Quevenco, Frances‐Catherine, Teunissen, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044123/ https://www.ncbi.nlm.nih.gov/pubmed/35496374 http://dx.doi.org/10.1002/dad2.12314

Ejemplares similares

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

Rationale and design of the ABOARD project (A Personalized Medicine Approach for Alzheimer's Disease)
por: Dreves, Maria A. E., et al.
Publicado: (2023)

Alzheimer’s disease CSF biomarkers: clinical indications and rational use
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
por: Teunissen, Charlotte E., et al.
Publicado: (2018)

Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making
por: van der Flier, Wiesje M., et al.
Publicado: (2017)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
por: Niazi, Sarfaraz
Publicado: (2022)

α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies
por: Kasuga, Kensaku, et al.
Publicado: (2012)

Biosafety Guidelines for Handling Microorganisms in the Teaching Laboratory: Development and Rationale(†)
por: Emmert, Elizabeth A. B.
Publicado: (2013)

GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
por: Lang, Frederick M., et al.
Publicado: (2020)

Rationale for reconsidering current regulations restricting use of hybrids in orange juice
por: Stover, Ed, et al.
Publicado: (2020)

Nutritional and Physical Prehabilitation in Elective Orthopedic Surgery: Rationale and Proposal for Implementation
por: Briguglio, Matteo, et al.
Publicado: (2022)

Early termination of pivotal trials in Alzheimer's disease—Preserving optimal value for participants and science
por: Gietl, Anton F., et al.
Publicado: (2022)

Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
por: Reddel, Helen K., et al.
Publicado: (2022)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines
por: Li, Jianhua, et al.
Publicado: (2021)

Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification
por: Parker, Richard A, et al.
Publicado: (2020)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
por: Bonaventura, Aldo, et al.
Publicado: (2020)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program
por: Saunders, Stina, et al.
Publicado: (2018)

Simplistic and complex thought in medicine: the rationale for a person-centered care model as a medical revolution
por: Reach, Gérard
Publicado: (2016)

Rationale for Determining the Functional Potency of Mesenchymal Stem Cells in Preventing Regulated Cell Death for Therapeutic Use
por: Naji, Abderrahim, et al.
Publicado: (2016)

Rationale for constant flow to optimize wastewater treatment and advanced water treatment performance for potable reuse applications
por: Tchobanoglous, George, et al.
Publicado: (2021)

The rationale of ethanol inhalation for disinfection of the respiratory tract in SARS-CoV-2-positive asymptomatic subjects
por: Salvatori, Pietro
Publicado: (2021)

Integrating nuclear receptor mobility in models of gene regulation
por: Gelman, Laurent, et al.
Publicado: (2006)

Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants
por: Dubois, Bruno, et al.
Publicado: (2023)

Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson’s Disease: Rationale, Design and Methods of the EXosomes in PArkiNson Disease (EXPAND) Study
por: Picca, Anna, et al.
Publicado: (2019)

The European tiered approach for virucidal efficacy testing – rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases
por: Eggers, Maren, et al.
Publicado: (2021)

Patient‐related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE
por: Teipel, Stefan J., et al.
Publicado: (2023)

“Doctor population ratio for India - The reality”
por: Deo, Madhav G.
Publicado: (2013)

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
por: de Wilde, Arno, et al.
Publicado: (2017)

Fisher’s historic 1922 paper On the dominance ratio
por: Charlesworth, Brian
Publicado: (2022)

Rationale for Quality Assurance in Fecal Egg Monitoring of Soil-Transmitted Helminthiasis
por: Hoekendijk, David J. L., et al.
Publicado: (2016)

Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial
por: Reimer, Toralf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_spdkhbv3173i75j1vgnnsfsgt7